Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Wedbush PacGrow 2021
Format: Panel presentation (Infectious Personality) and one-on-one investor meetings
Presentation Date & Time:
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.
Investor Relations Contact:
Source: Entasis Therapeutics Holdings Inc.